WVE
Wave Life Sciences Ltd.
NASDAQ · Healthcare · Biotechnology · SG
$4.86
+3.40%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 65.4M | 42.7M | 108.3M | 113.3M | 3.6M |
| Cost of Revenue | 2.3M | 8.9M | — | — | — |
| Gross Profit | 63.1M | 33.9M | 108.3M | 113.3M | 3.6M |
| Operating Expenses | |||||
| R&D Expense | 197.4M | 182.8M | 159.7M | 130.0M | 115.9M |
| SG&A Expense | 85.9M | 75.3M | 59.0M | 51.3M | 50.5M |
| General & Admin Expense | 85.9M | 75.3M | 59.0M | 51.3M | 50.5M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (2.3M) | (8.9M) | — | — | — |
| Total Operating Expenses | 281.0M | 249.3M | 218.7M | 181.3M | 166.4M |
| Cost and Expenses | 283.3M | 258.1M | 218.7M | 181.3M | 166.4M |
| Operating Income (EBIT) | (217.9M) | (215.4M) | (110.4M) | (68.0M) | (162.7M) |
| Non-Operating | |||||
| Interest Income | 15.2M | 10.5M | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 15.2M | 10.5M | — | — | — |
| Other Non-Op Income/Expense | 15.4M | 11.0M | 13.4M | 9.8M | 1.6M |
| Non-Operating Income (excl Interest) | (11.3M) | (11.0M) | (13.4M) | (9.8M) | (1.6M) |
| EBT (Pre-Tax Income) | (202.5M) | (204.4M) | (97.0M) | (58.2M) | (161.1M) |
| Income Tax Expense | — | — | — | (677.0K) | 681.0K |
| Bottom Line | |||||
| Net Income | (202.5M) | (204.4M) | (97.0M) | (57.5M) | (161.8M) |
| Earnings from Cont. Ops | (202.5M) | (204.4M) | (97.0M) | (57.5M) | (161.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (202.5M) | (204.4M) | (97.0M) | (57.5M) | (161.8M) |
| Per Share | |||||
| Basic EPS | ($1.09) | ($1.21) | ($0.70) | ($0.54) | ($2.05) |
| Diluted EPS | ($1.09) | ($1.21) | ($0.70) | ($0.54) | ($2.05) |
| Revenue Per Share | $0.32 | $0.25 | $0.78 | $1.07 | $0.05 |
| Shares | |||||
| Basic Shares Outstanding | 202.1M | 168.6M | 138.3M | 106.1M | 78.9M |
| Diluted Shares Outstanding | 202.1M | 168.6M | 138.3M | 106.1M | 78.9M |
| Profitability Metrics | |||||
| EBITDA | (197.5M) | (195.5M) | (88.3M) | (49.0M) | (151.0M) |
| D&A | 9.1M | 8.9M | 8.7M | 9.2M | 10.1M |
| EBIT | (206.6M) | (204.4M) | (97.0M) | (58.2M) | (161.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026